Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677338 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects
A Phase 2 study, sponsored by Otsuka Pharmaceutical Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01677338 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Co.. The registered enrollment target is 20 participants.
The verdict
NCT01677338, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is a multi-center, open-label comparison study and aimed to evaluate the preliminary performance of this 13C-uracil GEBT to examine its abilities of identifying abnormal (delayed) gastric emptying rates in subjects.
Interventions
- DRUG 13C-uracil
- DRUG 99mTc sulfur colloid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677338
The ClinicalTrials.gov registry entry for NCT01677338 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 13C-uracil is the first listed.
NCT01677338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01677338 about?
NCT01677338 is a clinical study titled "Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects". This study is a multi-center, open-label comparison study and aimed to evaluate the preliminary performance of this 13C-uracil GEBT to examine its abilities of identifying abnormal (delayed) gastric emptying rates in subjects.
What is the current status of trial NCT01677338?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-07. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01677338?
The interventions under investigation include: 13C-uracil (DRUG), 99mTc sulfur colloid (DRUG).
Who is sponsoring clinical trial NCT01677338?
This trial is sponsored by Otsuka Pharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.